Mergers and acquisitions activity has surged across multiple sectors since Q3 2024. Over the past several months, Goodwin advised on an impressive number of life sciences M&A deals of various types, sizes, and jurisdictions, including strategic sales, carveout deals, royalty acquisitions, reverse mergers, consolidations and distressed transactions. The sell- and buy-side deals listed below showcase the range and the depth of Goodwin's team and cement its positioning as the destination firm for life sciences M&A.
Sell-side deals include:
- Biotheus Enters Into Strategic Partnership with BioNTech
- Collegium Completes Acquisition of Ironshore Therapeutics
- Dr. Falk Pharma acquires Kynos Therapeutics
- Anika Therapeutics's Strategic Sale of Arthrosurface
- Curon Biopharmaceutical Sale of CN201 to Merck
- AlloVir and Kalaris Therapeutics to Merge
- Aerovate Therapeutics to Combine with Jade Biosciences in All-Stock Transaction
- Virios Therapeutics and Wex Pharmaceuticals Agree to Business Combination to Form Dogwood Therapeutics
Buy-side deals include:
- Ampersand Capital Partners Completes Acquisition of Nektar Therapeutics' PEG Reagent Manufacturing Business, Launching Newly Branded Gannet BioChem
- Royalty Pharma's Acquisition of Royalty Interest in Geron's Rytelo
- Royalty Pharma's Royalty Funding Agreement with Ascendis Pharma
- OncoC4 and AcroImmune Announce Merger
- Nerviano Medical Sciences Announces Strategic acquisition of atamparib, a Phase II-ready PARP7 Inhibitor, from Ribon Therapeutics
- Aditum Bio and Leads Biolabs' Formation of Oblenio Bio
Goodwin is a global leader in mergers and acquisitions, providing highly differentiated strategic and commercial advice and top-tier execution on more transactions annually than any other firm in the world.
The firm's full-service life sciences team is dedicated to providing practical and tactical advice on deal value and structure considerations, as well as on counseling life sciences clients (both public and private companies and investors in these companies) on the risks and rewards of M&A, on every side of the negotiating table.